StockData

Beta Bionics vs AVITA Medical

BBNX and RCEL side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BBNX and RCEL compare

Beta Bionics is the larger company, worth 1.8 times as much as AVITA Medical ($827M against $471M).

Beta Bionics grew revenue faster over the last twelve months (43.7% versus 1.00% for AVITA Medical).

AVITA Medical keeps more of each dollar of sales as profit, with a net margin of −57.0% compared with −65.3% at Beta Bionics.

Beta Bionics scores higher on the StockData Score (10 against 3 for AVITA Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBBNXRCEL
Size and price
Market cap$827M$471M
Share price$15.21$15.22
Change, 1 year−42.0%307%
Change, 5 years–7.9%
Beta (5Y)1.222.00
Employees420226
StockData Score
Total score10 (better)3
Valuation score1 (better)0
Growth score22
Performance score11
Health score6 (better)0
Dividend score00
Valuation
P/S6.5×6.2× (better)
P/B2.1×–
FCF yield−8.0%−5.2% (better)
Fair value$15.12–
Margin of safety−0.57%–
Growth
Revenue growth (TTM)43.7% (better)1.00%
Revenue growth, 5Y average–67.2%
Profitability
Gross margin58.6%81.6% (better)
Operating margin−72.7%−46.6% (better)
Net margin−65.3%−57.0% (better)
FCF margin−51.8%−32.5% (better)
Return on equity−23.9%–
Return on invested capital−64.4% (better)−261%
Financial health
Debt / equity0.00–
Interest coverage–−6.5×
Current ratio8.92 (better)0.41
Altman Z-score10.62 (better)−10.63
Piotroski F-score6 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions88.2%15.9%
Held by insiders9.3%2.7%
Insider net buying, 12 months−$5.6M$235K (better)
Short interest, % of float10.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.